A61K 38/18
Growth factors
Official title: Growth factors; Growth regulators
A61K38/18 (Growth factors) appears on 4,467 US grants and 7,690 published applications in this corpus.
Search patents in A61K- Granted patents
- 4,467
- Published applications
- 7,690
- Assignees
- 2,513
- Inventors
- 10,825
- Latest grant
- 29 Sep 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1981 | 1 | 0 |
| 1982 | 0 | 0 |
| 1983 | 2 | 0 |
| 1984 | 0 | 0 |
| 1985 | 0 | 0 |
| 1986 | 1 | 0 |
| 1987 | 1 | 0 |
| 1988 | 6 | 0 |
| 1989 | 8 | 0 |
| 1990 | 5 | 0 |
| 1991 | 17 | 0 |
| 1992 | 17 | 0 |
| 1993 | 21 | 0 |
| 1994 | 17 | 0 |
| 1995 | 24 | 0 |
| 1996 | 25 | 0 |
| 1997 | 75 | 0 |
| 1998 | 88 | 0 |
| 1999 | 73 | 0 |
| 2000 | 83 | 0 |
| 2001 | 93 | 34 |
| 2002 | 88 | 171 |
| 2003 | 74 | 222 |
| 2004 | 64 | 241 |
| 2005 | 67 | 232 |
| 2006 | 75 | 264 |
| 2007 | 85 | 274 |
| 2008 | 84 | 282 |
| 2009 | 112 | 275 |
| 2010 | 128 | 332 |
| 2011 | 124 | 315 |
| 2012 | 183 | 282 |
| 2013 | 171 | 378 |
| 2014 | 242 | 429 |
| 2015 | 257 | 423 |
| 2016 | 245 | 417 |
| 2017 | 271 | 396 |
| 2018 | 235 | 379 |
| 2019 | 275 | 390 |
| 2020 | 215 | 341 |
| 2021 | 193 | 342 |
| 2022 | 206 | 356 |
| 2023 | 142 | 266 |
| 2024 | 164 | 280 |
| 2025 | 142 | 218 |
| 2026 | 68 | 151 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Subgroups
Granted patents
- A61K 38/1825Fibroblast growth factor [fgf]925
- A61K 38/1858Platelet-derived growth factor [pdgf]840
- A61K 38/1841Transforming growth factor [tgf]781
- A61K 38/1816Erythropoietin [epo]658
- A61K 38/1875Bone morphogenic factor618
- A61K 38/185Nerve growth factor [ngf]511
- A61K 38/1808Epidermal growth factor [egf] urogastrone386
- A61K 38/1833Hepatocyte growth factor218
All 10 subgroupsShow fewer
Recent patents
- Use of BMP9 in combination with NK cell and PD-L1 antibody in preparing medicament for treating liver cancer29 Sep 2026US 12,746,274 B2Sun Yat-Sen University
- Hyaluronic acid derivative and use thereof29 Sep 2026US 12,746,306 B2Amtixbio Co., Ltd.
- Growth and differentiation factor 15 for treatment of proliferative vitreoretinopathy therapy8 Sep 2026US 12,728,152 B2The Board of Trustees of the Leland Stanford Junior University
- Method for isolating and culturing cord blood stem cells expressing GDF-3 at high level, and use of GDF-31 Sep 2026US 12,723,065 B2PRIMORIS THERAPEUTICS Co., Ltd.
- Methods of treating HIV-HAART induced partial lipodystrophy with FGF21 protein variant fc fusion proteins25 Aug 2026US 12,714,739 B2Novartis AG
- Fgf21 compound / glp-1r agonist combinations with optimized activity ratio8 Oct 2026US 2026/0306587 A1Sanofi
- Lifting agent with therapeutics8 Oct 2026US 2026/0306594 A1Boston Scientific Scimed, Inc.
- Anti-vegf protein compositions and methods for producing the same8 Oct 2026US 2026/0308231 A1Regeneron Pharmaceuticals, Inc.
- Anti-vegf protein compositions and methods for producing the same8 Oct 2026US 2026/0308232 A1Regeneron Pharmaceuticals, Inc.
- Anti-vegf protein compositions and methods for producing the same8 Oct 2026US 2026/0308233 A1Regeneron Pharmaceuticals, Inc.
Most cited
By later US patents
- Renewable neural implant device and method1,456US 5,554,148 ABrown University Research Foundation · 1996
- Three dimensional cell protector/pore architecture formation for bone and tissue constructs778US 7,713,542 B2ADA Foundation · 2010
- Method for manufacturing a porous ceramic scaffold having an organic/inorganic hybrid coating layer containing a bioactive factor777US 8,734,831 B2Snu R&Db Foundation · 2014
- Controlled release formulations of trophic factors in ganglioside-lipsome vehicle653US 5,073,543 AG. D. Searle & Co. · 1991
- Method and compositions for the treatment and repair of defects or lesions in cartilage470US 5,206,023 A1993